NVO

High-End Earnings Visibility Analytics Raise Ranking of Novo Nordisk A/S (NVO) to Strong Buy

By Portfolio Grader
With a $98.0 billion market value, Novo Nordisk A/S (NYSE:NVO) ranks in the top 10% of its industry group, Pharmaceuticals, and in the top 10% of its sector group, Health Care, in market value. From the viewpoint of investment attractiveness, the stock's current Portfolio Grader score places it 2 among the 133 companies in this industry group, positioning it among the leaders; in the top decile of the sector with a ranking of 29 among the 785 companies in the sector, and number 206 in the nearly 5,000 company Portfolio Grader universe.

Exceptional Quant Score Analytics Raise Ranking of Novo Nordisk A/S (NVO) to Strong Buy

By Portfolio Grader
With a $97.2 billion market value, Novo Nordisk A/S (NYSE:NVO) ranks in the top 10% of its industry group, Pharmaceuticals, and in the top 10% of its sector group, Health Care, in market value. From the viewpoint of investment attractiveness, the stock's current Portfolio Grader score places it 3 among the 133 companies in this industry group, positioning it among the leaders; in the top decile of the sector with a ranking of 33 among the 783 companies in the sector, and number 218 in the nearly 5,000 company Portfolio Grader universe.

Novo Nordisk A/S’s (NVO) Solid Quant Score Makes it a Buy

By Portfolio Grader
The current recommendation of Buy for Novo Nordisk A/S (NYSE:NVO) is derived using Louis Navellier's investing methods and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for the last month.

Earnings Visibility Makes Novo Nordisk A/S (NVO) a Buy

By Portfolio Grader
Novo Nordisk A/S (NYSE:NVO) is a $93.3 billion in market value constituent of the Pharmaceuticals GICS industry group where Portfolio Grader's current ranking for NVO puts it 29 among the 135 companies in this industry group, giving it a well above-average position. NVO is ranked in the top half of the sector with a ranking of 203 among the 783 companies in the sector and number 1,464 in the 5000 company Portfolio Grader company universe.

Novo Nordisk A/S’s (NVO) Stock Has Hold Recommendation Remain in Place

By Portfolio Grader
Portfolio Grader currently ranks Novo Nordisk A/S (NYSE:NVO) a Hold. The approach to investing incorporated in this analytical tool developed by Louis Navellier researches and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. The current Portfolio Grader recommendation on the shares has been in place for the last month.

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Soars on New CEO News

By William White, InvestorPlace Writer
Teva Pharmaceutical (TEVA) stock was flying high today following news of a new CEO that will be joining the company soon.

10 Biotech Stocks With Game-Changing Dates in Q3

By James Brumley, InvestorPlace Feature Writer
If you're looking to speculate in the inherent volatility of biotech stocks, here are ten impending events that could cause those fireworks.

5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio

By
VIVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies. Here's why VVUS stock is a must

Global Blood Therapeutics Inc (GBT) Stock Soars on Takeover Talk

By Karl Utermohlen, InvestorPlace Writer
Global Blood Therapeutics (GBT) stock is rising as the company is being targeted for a takeover by another pharma corporation. Here's what's happenig

9 Top Pharmaceutical Stocks to Buy for the Dividends

By James Brumley, InvestorPlace Feature Writer
Fans of dividends don't have to completely abandon all hope for growth too -- these top pharmaceutical stocks offer the best of both worlds.

3 European Stocks to Buy for Big-Time Dividends

By Aaron Levitt, InvestorPlace Contributor
Don't overlook European stocks when it comes to dividends. Companies like Diageo (DEO), Novo Nordisk (NVO) and Eni (E) are stellar.

3 Big Pharma Stocks Under Pressure From Washington

By Profit Scanner
We cover the technical condition of three Big Pharma stocks, with the help of Profit Scanner, to determine where their prices may be headed.

7 Healthcare Stocks That Are Investor Poison

By Louis Navellier, Editor, Growth Investor
You can't blindly buy stocks in healthcare because there are some that have some serious problems.

5 Pharmaceuticals Stocks to Sell Now

By Portfolio Grader
The ratings of 5 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

14 Pharmaceuticals Stocks to Sell Now

By Portfolio Grader
The overall ratings of 14 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

12 Pharmaceuticals Stocks to Sell Now

By Portfolio Grader
This week, the overall grades of 12 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

9 Pharmaceuticals Stocks to Sell Now

By Portfolio Grader
This week, 9 Pharmaceuticals stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Why American Airlines Group Inc (AAL), Novo Nordisk A/S (ADR) (NVO) and Synchrony Financial (SYF) Are 3 of Today’s Worst Stocks

By James Brumley, InvestorPlace Feature Writer
American Airlines (AAL), Novo Nordisk (NVO) and Synchrony Financial (SYF) couldn't win for losing on Tuesday. Here's the deal.

88 Blue Chip Stocks to Consider This Week

By
During these times it pays to stay on top of profit opportunities. Today's post is a great place to start with these latest Portfolio Grader ratings
Load More